BioLife Solutions, Inc. Provides Revenue Guidance for 2021
March 22, 2021 at 04:05 pm EDT
Share
BioLife Solutions, Inc. provided revenue guidance for 2021. Revenue guidance is based on current expectations for existing business, and includes anticipated contributions from acquisition of Stirling Ultracold, which is expected to close on or before May 1, 2021. Total revenue for 2021 is expected to be in the range of $101 million to $110 million, reflecting year-over-year revenue growth of 110% to 129%.
BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Its expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. Its biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death which result when cells and tissues are subjected to reduced temperatures. Its bioproduction tools portfolio includes human platelet lysates for cell expansion. It is a provider of biological and pharmaceutical storage and cold chain logistics. Its monitoring systems allow customers real time tracking of the storage temperatures of their materials throughout the logistics process. It operates about five storage facilities in the United States and one facility in the Netherlands.
BIOLIFE SOLUTIONS, INC. 
